The disclosure provides methods that facilitate disease management by providing for early detection of metabolic changes that differentiate critically ill-COVID-19 patients under mechanical ventilation at the intensive care unit (ICU) who are likely to exhibit faster recovery.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents (TA) within the GI tract and in particular to an antrum wall (AW). Particular embodiments provide a swallowable device (SD) such as a capsule for delivering drugs or other TA into the AW. The SD may contain a pressure sensitive component or assembly which triggers release and insertion of a therapeutic agent preparation (TAP) comprising at least one TA into the AW in response to external pressure, such as pressure applied to the swallowable capsule or other SD by antrum contractions. Particular embodiments of the SD may be shaped so that they self-align within an antrum to properly orient before injection of the TAP into the AW. Embodiments of the invention are particularly useful for orally delivering drugs or other TAs which are degraded within the GI tract and require parenteral injection.

A ventilator system is capable of displaying complex information patterns in a GUI, thereby allowing a clinician to get subtract complex information from multiple parameters inputs.

A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, which can include information relating to a potential respiratory equilibrium, and a duration of safe apnoea is determined from the obtained information.

A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, which can include information relating to a potential respiratory equilibrium, and a duration of safe apnoea is determined from the obtained information.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

Medical techniques include systems and methods for administering a positive pressure ventilation, a positive end expiratory pressure, and a vacuum to a person. Approaches also include treating a person with an intrathoracic pressure regulator so as to modulate or upregulate the autonomic system of the person, and treating a person with a combination of an intrathoracic pressure regulation treatment and an intra-aortic balloon pump treatment.

The present invention generally relates to a process suitable for extracorporeal lung support. The process comprises contacting blood with a dialysis liquid separated by a semipermeable membrane. Oxygen is introduced into blood and/or into the dialysis liquid prior to contacting blood and dialysis liquid being separated by the semipermeable membrane. The process is versatile and allows for blood oxygenation as well as removal of at least one undesired substance occurring in the blood, selected from carbon dioxide, bicarbonate and hydrogen cations, from blood. Thereby, the present invention takes advantage of the Haldane effect in the extracorporeal contacting step. The undesired substance can be efficiently transported across a semipermeable membrane to the dialysis liquid. In contrast to extracorporeal carbon dioxide removal methods of the prior art (ECCCbR), the present invention employs a versatile dialysis liquid that allows to adjust the pH and buffering capacity of the dialysis liquid, to add fluids to the dialysis liquid and/or to the blood and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. The present invention also provides regeneration and recycling of the dialysis liquid, and thus for its repeated use. The present invention is suitable for treating human or animal subjects suffering from lung failure or lung disorders.

A mechanical kidney transplant designed may include a four modules designed to interconnect to clean blood. The first module may include a plurality of pump modules and a resin gel regeneration module, wherein the first module is operatively attached to a patient's iliac artery, iliac vein, and bladder. The second module may be operatively attached to the first module and may include storage and pump systems. The third module may be operatively attached to the first and fourth modules and may include a housing with ports for inflow/outflow of the blood and the physiologic resin gel between the first module and the fourth module. The fourth module may include at least one dialyzer fiber sized to accommodate a volume of blood flowing therethrough and an area surrounding the dialyzer fiber may be sized to accommodate a volume of a physiologic resin gel flowing counter current to the blood.

A plurality of flow rate values associated with pressurized air directed to an airway of a user of a respiratory therapy system is received. A plurality of pressure values associated with the pressurized air directed to the airway of the user is received. A first time associated with a first breath of the user and a second time associated with a second breath of the user are identified. The plurality of flow rate values is filtered based at least in part on the identified first time and the identified second time. The filtering produces a subset of the plurality of flow rate values. An intentional leak characteristic curve for the respiratory therapy system is determined using at least two of the subset of the plurality of flow rate values and the corresponding pressure values for said at least two of the subset of the plurality of flow rate values.